These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29655626)

  • 1. A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage.
    Dagan R; Ben-Shimol S; Simell B; Greenberg D; Porat N; Käyhty H; Givon-Lavi N
    Vaccine; 2018 May; 36(20):2774-2782. PubMed ID: 29655626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.
    Ojal J; Hammitt LL; Gaitho J; Scott JAG; Goldblatt D
    Vaccine; 2017 Aug; 35(35 Pt B):4652-4657. PubMed ID: 28739116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
    Dagan R; Givon-Lavi N; Porat N; Greenberg D
    Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2016 Aug; 34(36):4313-20. PubMed ID: 27422342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV; Toh ZQ; Clutterbuck EA; Balloch A; Marimla RA; Tikkanen L; Lamb KE; Bright KJ; Rabuatoka U; Tikoduadua L; Boelsen LK; Dunne EM; Satzke C; Cheung YB; Pollard AJ; Russell FM; Mulholland EK
    J Allergy Clin Immunol; 2016 Jun; 137(6):1772-1779.e11. PubMed ID: 26825000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
    Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine.
    Akinsola AK; Ota MO; Enwere GC; Okoko BJ; Zaman SM; Saaka M; Nsekpong ED; Odutola AA; Greenwood BM; Cutts FT; Adegbola RA
    PLoS One; 2012; 7(2):e31050. PubMed ID: 22363544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme.
    Wouters I; Van Heirstraeten L; Desmet S; Blaizot S; Verhaegen J; Goossens H; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2018 Jan; 36(1):15-22. PubMed ID: 29180027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries.
    Voysey M; Fanshawe TR; Kelly DF; O'Brien KL; Kandasamy R; Shrestha S; Thorson S; Hinds J; Pollard AJ
    Clin Infect Dis; 2018 Mar; 66(6):913-920. PubMed ID: 29069415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial.
    Kandasamy R; Gurung M; Thorson S; Yu LM; Galal U; Voysey M; Kelly S; Wahl B; Berbers G; Finnegan K; Ansari I; Paudel K; Murdoch DR; O'Brien KL; Kelly DF; Goldblatt D; Shrestha S; Pollard AJ
    Lancet Infect Dis; 2019 Feb; 19(2):156-164. PubMed ID: 30635252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy.
    Dagan R; Givon-Lavi N; Greenberg D; Fritzell B; Siegrist CA
    J Infect Dis; 2010 May; 201(10):1570-9. PubMed ID: 20384496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of IgG antibody following routine infant immunization with the 7-valent pneumococcal conjugate vaccine.
    Grant LR; Burbidge P; Haston M; Johnson M; Reid R; Santosham M; Goldblatt D; O'Brien KL
    Pediatr Infect Dis J; 2015 May; 34(5):e138-42. PubMed ID: 25621761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
    Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers.
    Gurung M; Bijukchhe SM; Hariri P; Voysey M; Kandasamy R; Thorson S; Maskey P; Pandit R; Shrestha B; Gautam MC; Maharjan M; Lama L; Acharya B; Basi R; K C M; O'Reilly P; Shrestha S; Ansari I; Shah GP; Kelly S; O'Brien KL; Goldblatt D; Kelly DF; Murdoch DR; Pollard AJ; Shrestha S
    Pediatr Infect Dis J; 2021 Oct; 40(10):937-943. PubMed ID: 34292271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of a pneumococcal conjugate vaccination program on the nasopharyngeal carriage, serotype distribution and antimicrobial resistance of Streptococcus pneumoniae among healthy children in Turkey.
    Soysal A; Karabağ-Yılmaz E; Kepenekli E; Karaaslan A; Cagan E; Atıcı S; Atınkanat-Gelmez G; Boran P; Merdan S; Hasdemir U; Söyletir G; Bakır M
    Vaccine; 2016 Jul; 34(33):3894-900. PubMed ID: 27269059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.